PURPOSE: To evaluate the risk of a subsequent primary thyroid cancer (SPTC) in patients with common invasive cancers, with attention to latency trends and histology associations. METHODS: Patients with one of 10 common invasive cancers were followed from 1975 to 2008 in 9 registries participating in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. Standardized incidence ratios (SIRs) for SPTC were determined by the multiple primary-SIR program in SEER*Stat. RESULTS: A total of 2502 SPTCs were observed. Greatly elevated SIRs for SPTC were noted for 9 of 10 evaluated cancers in the 12 months after initial diagnosis. The SIRs remained elevated 12-59 months after diagnosis for all cancers except leukemia, uterine, and bladder cancers. Increased risks persisted 60-119 months beyond diagnosis for renal (SIR 2.56) and breast cancer (SIR 1.16); and 120+ months for renal cancer (SIR 2.46). Increased SPTC risk after renal and female breast cancers was mostly seen in nonirradiated patients. The principal histology association was between papillary thyroid cancer and renal cell carcinomas. CONCLUSIONS: Many common cancers are associated with increased risk of SPTC beyond 12 months of initial diagnosis. Although this can be explained partly by continued surveillance bias, radiation effects, and known rare familial associations for some tumors, these factors alone are unlikely to explain the persistent, significant two-way association with renal and breast cancers. Additional research is needed to further define the biological and environmental mechanisms underlying these associations.
PURPOSE: To evaluate the risk of a subsequent primary thyroid cancer (SPTC) in patients with common invasive cancers, with attention to latency trends and histology associations. METHODS:Patients with one of 10 common invasive cancers were followed from 1975 to 2008 in 9 registries participating in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. Standardized incidence ratios (SIRs) for SPTC were determined by the multiple primary-SIR program in SEER*Stat. RESULTS: A total of 2502 SPTCs were observed. Greatly elevated SIRs for SPTC were noted for 9 of 10 evaluated cancers in the 12 months after initial diagnosis. The SIRs remained elevated 12-59 months after diagnosis for all cancers except leukemia, uterine, and bladder cancers. Increased risks persisted 60-119 months beyond diagnosis for renal (SIR 2.56) and breast cancer (SIR 1.16); and 120+ months for renal cancer (SIR 2.46). Increased SPTC risk after renal and female breast cancers was mostly seen in nonirradiated patients. The principal histology association was between papillary thyroid cancer and renal cell carcinomas. CONCLUSIONS: Many common cancers are associated with increased risk of SPTC beyond 12 months of initial diagnosis. Although this can be explained partly by continued surveillance bias, radiation effects, and known rare familial associations for some tumors, these factors alone are unlikely to explain the persistent, significant two-way association with renal and breast cancers. Additional research is needed to further define the biological and environmental mechanisms underlying these associations.
Authors: Parveen Bhatti; Lene H S Veiga; Cécile M Ronckers; Alice J Sigurdson; Marilyn Stovall; Susan A Smith; Rita Weathers; Wendy Leisenring; Ann C Mertens; Sue Hammond; Debra L Friedman; Joseph P Neglia; Anna T Meadows; Sarah S Donaldson; Charles A Sklar; Leslie L Robison; Peter D Inskip Journal: Radiat Res Date: 2010-10-06 Impact factor: 2.841
Authors: C D Malchoff; M Sarfarazi; B Tendler; F Forouhar; G Whalen; V Joshi; A Arnold; D M Malchoff Journal: J Clin Endocrinol Metab Date: 2000-05 Impact factor: 5.958
Authors: Shu-Chun Chuang; Mia Hashibe; Guo-Pei Yu; Anh D Le; Wei Cao; Eric L Hurwitz; Jian-Yu Rao; Alfred I Neugut; Zuo-Feng Zhang Journal: Cancer Lett Date: 2005-07-21 Impact factor: 8.679
Authors: Thekkepat C Sandeep; Mark W J Strachan; Rebecca M Reynolds; David H Brewster; Ghislaine Scélo; Eero Pukkala; Kari Hemminki; Aage Anderson; Elizabeth Tracey; Søren Friis; Mary L McBride; Chia Kee-Seng; Vera Pompe-Kirn; Erich V Kliewer; Jon M Tonita; Jon G Jonasson; Carmen Martos; Paolo Boffetta; Paul Brennan Journal: J Clin Endocrinol Metab Date: 2006-02-14 Impact factor: 5.958
Authors: C Rubino; F de Vathaire; M E Dottorini; P Hall; C Schvartz; J E Couette; M G Dondon; M T Abbas; C Langlois; M Schlumberger Journal: Br J Cancer Date: 2003-11-03 Impact factor: 7.640
Authors: Sarah M Nielsen; Michael G White; Susan Hong; Briseis Aschebrook-Kilfoy; Edwin L Kaplan; Peter Angelos; Swati A Kulkarni; Olufunmilayo I Olopade; Raymon H Grogan Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-02 Impact factor: 4.254
Authors: Sara E Murray; David F Schneider; Philip S Bauer; Rebecca S Sippel; Herbert Chen Journal: J Am Coll Surg Date: 2013-03-20 Impact factor: 6.113
Authors: Jeffrey J Tomaszewski; Robert G Uzzo; Brian Egleston; Anthony T Corcoran; Reza Mehrazin; Daniel M Geynisman; John A Ridge; Colleen Veloski; Neil Kocher; Marc C Smaldone; Alexander Kutikov Journal: Ann Surg Oncol Date: 2014-09-10 Impact factor: 5.344
Authors: Sara J Schonfeld; Lindsay M Morton; Amy Berrington de González; Rochelle E Curtis; Cari M Kitahara Journal: Cancer Epidemiol Date: 2019-12-26 Impact factor: 2.984
Authors: M M Yalcin; A E Altinova; C Ozkan; F Toruner; M Akturk; O Akdemir; T Emiroglu; D Gokce; A Poyraz; F Taneri; I Yetkin Journal: Acta Endocrinol (Buchar) Date: 2016 Apr-Jun Impact factor: 0.877